Literature DB >> 11127941

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

A Montazeri1, M Boucaud, F Lokiec, F Pinguet, S Culine, R Déporte-Féty, N Albin, B Laguerre, A Goupil, R Bugat, P Canal, E Chatelut.   

Abstract

The inter- and intraindividual variabilities in topotecan clearance (CL) were explored using a population pharmacokinetic approach. Total (lactone + hydroxy acid) topotecan plasma concentrations were obtained in 31 women with metastatic epithelial ovarian cancer treated by the 30-min intravenous infusion on 5 subsequent days. The data corresponding to three occasions (days 1 and 5 of cycle 1, and day 1 of cycle 2), were analyzed using the nonlinear mixed effect model program. A large interindividual variability was observed, with CL varying from 9.1 to 42.51 per hour (mean 21.0). Topotecan CL was related to serum creatinine level, and age. A close relationship was also observed between topotecan CL and creatinine clearance. Intraindividual variability both within cycle 1 and between the two first cycles was limited, with a mean variation of -2+/-17%, and + 5+/-20%, respectively. A limited sampling strategy using Bayesian estimation based on two samples (5 min before the end of the 30-min infusion, and 4 h after the end of infusion) was developed. The results of this study combine relationships between topotecan pharmacokinetic parameters and patient covariates that may be useful for a priori dose adjustment, and convenient sampling procedure that can be used for further studies and drug monitoring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127941     DOI: 10.1007/s002800000161

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  6 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors.

Authors:  Fei Tang; Eleftheria Tsakalozou; Susanne M Arnold; Chee M Ng; Markos Leggas
Journal:  Invest New Drugs       Date:  2019-02-28       Impact factor: 3.850

4.  Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.

Authors:  Thorsten Simon; Alfred Längler; Urs Harnischmacher; Michael C Frühwald; Norbert Jorch; Alexander Claviez; Frank Berthold; Barbara Hero
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

Review 5.  Toxicity patterns of cytotoxic drugs.

Authors:  Etienne Chatelut; Jean-Pierre Delord; Pierre Canal
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

6.  Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.

Authors:  F Léger; W J Loos; J Fourcade; R Bugat; M Goffinet; R H J Mathijssen; J Verweij; A Sparreboom; E Chatelut
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.